Poly ADP-ribose polymerase (PARP) inhibition can potentiate responses to PD-1/PD-L1 inhibition via a number of mechanisms including increased TMB secondary to unrepaired DNA damage (especially in patients with DDR gene mutations), enhanced PD-L1 expression, and immune cell infiltration into the tumor microenvironment. Here, CD274 is linked to neoplasm.